Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pradigastat

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AcetatesAminopyridines

Narrower (1)

LCQ908

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pradigastat disposition in humans: in vivo and in vitro investigations
Abstract 1. Pradigastat is a potent and specific diacylglycerol acyltransferase-1 (DGAT1) inhibitor effective in lowering… Expand
2016
2016
Assessment of pharmacokinetic drug‐drug interaction between pradigastat and atazanavir or probenecid
Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, has activity in common metabolic diseases associated with… Expand
2016
2016
The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions.
The DGAT1 inhibitor, pradigastat, demonstrated a mild phototoxicity signal in preclinical studies. Therefore, this clinical trial… Expand
2016
2016
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans
Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To… Expand
Highly Cited
2015
Highly Cited
2015
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
BackgroundFamilial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2015
2015
Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects
Pradigastat is a potent and selective inhibitor of diacylglycerol acyltransferase 1, an enzyme highly expressed in the small… Expand
2015
2015
Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
OBJECTIVE An in vitro drugdrug interaction (DDI) study was performed to assess the potential for pradigastat to inhibit breast… Expand
2015
2015
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor
Background and ObjectivePradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial… Expand
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
2014
2014
Pharmacokinetic and pharmacodynamic drug–drug interaction assessment between pradigastat and digoxin or warfarin
Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic… Expand
2013
2013
The DGAT1 inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE